Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia

Fig. 4

Triptolide caused a decrease in the protein levels of c-Myc in a dose and time dependent manner (a). On evaluating mRNA levels, treatment with triptolide reduced c-Myc transcription (b). Also, an increase in number of cells at the G1/S interphase with a decrease in G2/M phase of both THP-1 (c) and KG1a (d) cells were seen with a corresponding increase in the levels of the cell cycle regulator protein p21 with triptolide (e). Inhibition of c-Myc using a specific c-Myc inhibitor led to a decrease in cell proliferation (f). n = 3, *p < 0.05 compared to control untreated cells, data shows mean ± SD

Back to article page
\